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Abstract
Background: Last this year in this journal, Barbour and colleagues reported a study of “marketing trials” in leading
medical journals (Trials 2016;17:31). In this commentary I discuss their research, describe new analyses of the study
cohort and consider measures to address marketing within academic medical literature.
Discussion: Barbour et al. sought to identify a subgroup of “marketing trials” within leading medical journals, but in
reality, nearly all industry-financed trials serve marketing functions, and many exhibit marketing-related features,
including biases, in their framing, methodology or reporting. I conducted new analyses of the cohort of Barbour et al.,
showing that most trials funded exclusively by drug manufacturers had direct involvement of the manufacturer in
design, analysis and reporting, and features supportive of product seeding. However, these commercial enterprises
were without exception presented to journal readers as academic-led projects, using attributional spin, which should
itself be considered an important form of marketing bias. Barbour et al. correctly conclude that commercial bias in
industry clinical trials articles often requires expertise to recognize, and in many cases cannot be identified from the
published journal report. Several potential remedies are discussed, including independent clinical research, data
sharing, improved reporting guidance, improved tools for assessing research quality, reforms to article attribution,
submission checklists and new editorial standards.
Conclusion: Medicine’s journals have a responsibility to uphold rigorous scientific and reporting standards, require
ready trials data access and ensure the commercial dimensions of research are brought prominently to their readers’
attention. Failure to meet these responsibilities constitutes an enduring threat to the integrity of biomedical literature.
Keywords: Pharmaceutical industry, Marketing, Seeding trial, Marketing trial, Bias, Authorship, Transparency, Disclosure,
Research integrity, Guidelines, Checklist
Background
Last year in this journal, Barbour and colleagues pub-
lished an analysis of 194 journal articles with the striking
claim that “21% of drug trials … in the leading general
medical journals had characteristics consistent with the
aim of marketing the product” [1]. Their study raises im-
portant questions about how marketing works in
industry-financed clinical trials and the journal articles
which report them, and what measures should be taken
to address its influence.
Discussion
Marketing can be defined straightforwardly as the pro-
motion of any product, service or organization to its
customers, but the term “marketing trial” is ambiguous.
Its usage is similar to the term “seeding trial”, in which
prospective customers are involved in fatuous research
to familiarize them with a commercial product, in the
hope they will continue to prescribe it after the trial has
ended [2–6]. But are Barbour et al. claiming that one
fifth of the clinical trials in leading journals, and sub-
stantially more in the Lancet and New England Journal
of Medicine, are such cynical enterprises?
The answer is no. Fatuous seeding trials are more
likely to be published in lower tier journals, and may not
involve controlled designs. Some trials in leading journals
have been designed in consultation with regulators to win
marketing approval, and while they may be conservative,
most are not fatuous. Thus, if the figure of 21% from
Barbour et al. were taken as a measure of the preva-
lence of wholly worthless research in leading journals,
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it would be an overestimate. Yet conversely, it would
be a significant underestimate of the prevalence of
marketing — and probably marketing bias — within
this literature.
Marketing functions and marketing-related features
To understand the interaction between marketing and
clinical trials, it is necessary to shift perspective from
“marketing trials”, which define only one point along a
spectrum of commercial influence, and map the problem
more systematically. In particular, it is helpful to separate
the marketing functions industry trials perform from their
marketing-related features, that is, the details of framing,
design and reporting which have been commercially con-
figured the better to serve marketing goals.
As Table 1 illustrates, various strategic considerations
determine the choice of trials manufacturers undertake.
Once the selection is made, however, trials serve numer-
ous marketing functions. Most obviously, they generate
reservoirs of data, as a basis for evidence-based medicine,
and equally, evidence-based marketing. This is the case
for off-label as well as on-label research, and a seemingly
innocuous trial exploring a new use of a drug may consti-
tute off-label marketing — indeed, this is sometimes a
specific strategy [7].
Trials are also a tool for recruiting and leveraging key
opinion leaders (KOLs) [8, 9]. A large trial keeps in place
a substantial group of KOLs, maintains high-level interest
and helps the company forge relationships with and among
KOLs, creating a network of “influencers” to serve the
company’s interests. Large long-term trials are also used
directly to promote drugs: for example, most angiotensin
receptor blockers had long-term outcomes trials [10–15]
which addressed clinically relevant issues but were also
used during their courses to generate interest and product
differentiation, for instance, at congresses or through jour-
nal publications. Finally, trials can be used for product
seeding, by spreading the study population thinly across
numerous investigator sites, each of which enrolls relatively
few patients. Such “seeding” features do not only function,
however, to familiarize prescribers with the product. They
promote regular contact between the company’s represen-
tatives and prescribers, building familiarity and trust and
assisting sales not only of the study drug, but of other
products. They also facilitate “internal marketing”, that is,
generating enthusiasm for the product within the com-
pany; they help local teams acquire greater knowledge of
the product; and when recruitment is a challenge, they
may enable trials to be completed more quickly. There
may also be regulatory considerations; for instance, some
countries require their own nationals to be involved in
pivotal trials for a license to be granted, and the need for
an ethnically diverse population may also increase the
number of study sites and countries [16].
None of these marketing functions, with the excep-
tion of seeding, necessarily compromises the quality
of the science in industry trials. The best industry tri-
als of promising new drugs, including many pivotal
regulatory trials where the company stands to lose
billions if the study fails, have robust designs and are
objectively reported. In other cases, however, market-
ing encroaches into the trial’s features, influencing the
framing of research questions, steering the design
choices, driving the accumulation of biases and shap-
ing the reporting of results (Table 1) [17–25]. The
foremost difficulty with industry research is not the
fatuous marketing trial, but the coexistence within the
same clinical studies of defensible science and subtle
marketing spin, rendering the results harder to evalu-
ate, but easier to sell.
Table 1 Interactions between marketing and clinical trials
General influences on the choice and design of industry trials
• Clinical/commercial product profile, competitor landscape,
opportunities and risks
• Regulatory requirements
• Cost, time, patient recruitment and logistics
Marketing functions of industry trials
• Generating commercially useful data
• Engaging, organizing and retaining key opinion leaders
• Building relationships with investigators and their institutions,
including internationally
• Seeding — familiarizing clinicians with use of a product such that
they continue using it after the trial
• Generating publicity, interest and prestige for a drug and its
manufacturer, for instance, through publications, congresses and
material for sales representatives
• Internal marketing — building company enthusiasm and product
understanding
Marketing-related features of industry trials
A. Research question
• May be meaningful or fatuous; ambitious or conservative; balanced
or loaded; appropriately or inappropriately framed
B. Commercial choices and biases in design, conduct and analysis
• Not all commercial trials are biased, and marketing can be based on
unbiased data and reporting
• Nonetheless, many industry trials involve commercially expedient
methodological choices and biases. These may be unconscious or
planned
• Randomized studies — multifarious opportunities for commercially
expedient decisions and biases, often closely related to the clinical
particularities of the trial
C. Commercial choices and biases in reporting
• Non-reporting of unhelpful trials and data
• Delayed, obscure or underreporting: choice of journal, website or
congress proceedings
• Published articles — selective reporting of favourable vs. unfavourable
results; inferring greater clinical relevance than the data justify; framing,
interpretation, visual spin, rhetoric and conclusions
• Overreporting of favourable findings in secondary publications
• Attributional spin, highlighting the role of academics and understating
that of manufacturers, is endemic in medical journal articles
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Corporate authors, widespread seeding and attributional
spin
Who is responsible for commercial encroachment into
this science? To some degree, the academic authors are
culpable, whether through lack of awareness or poor
judgement. Many such individuals are trusted partners
who enjoy financial relationships with the manufacturers
[26, 27] and know that if they disappoint their patrons,
they may not be invited back. The primary culprits, how-
ever, are the companies themselves, who in most cases are
proprietors and corporate authors of this research, and its
one essential component: the academic authors and insti-
tutions recruited into these projects are replaceable by
others [28]. To refer to companies as mere “sponsors” of
these trials or providers of “funding” or “support” conceals
their true role, and such terms should be discarded.
To demonstrate the extent of corporate involvement,
it is first necessary to distinguish between true industry
projects funded and instigated by manufacturers, and
studies that merely received a degree of industry funding.
Barbour et al. kindly shared their database to enable me to
undertake this analysis (see Additional file 1). A total of
68 trials in their cohort of 194 studies received exclu-
sive manufacturer funding, and in the large majority of
these trials, the company was involved directly in design
(82%), analysis (83%) and also reporting (76%), deploying
company employees as coauthors (88%) and using trade
writers (69%). Lundh and colleagues have previously re-
ported similar findings in this journal for a cohort of arti-
cles published in the Lancet [29]. Furthermore, designs
suggestive of seeding were not limited to a few “seeding
trials” but were commonplace among the manufacturer-
funded trials in the cohort. The median number of investi-
gator centres in trials funded exclusively by the drug
manufacturer was 111, but remarkably, the median num-
ber of patients randomized per centre was only 9. These
findings suggest that seeding is a widespread feature of
manufacturer-financed clinical research.
Yet while these trials are corporate projects, they are
not presented to readers as such. The most visible form
of bias in this literature is attributional bias, wherein
the role of the academic participants in the study is
highlighted and industry’s downplayed [28, 30, 31]. This
ensures industry work is presented to readers under the
lead authorship of credible academics, and by reducing
the impression of commercial influence, may also increase
the prospect of journal publication [32]. Barbour et al. did
not investigate attributional spin, but I identified all the
industry-financed articles in their cohort with both aca-
demics and industry employees as coauthors, which num-
bered 70 in total (see Additional file 1). Among these, all
70 had academic lead authors: there was not a single art-
icle where an employee of the company fronted the work.
This is the first time the systematic fronting of industry
projects by academics has been reported for a defined co-
hort of articles.
Spotting marketing and bias
Readers of journal articles that report clinical trials
should always check for industry funding, industry involve-
ment in research and reporting, ties between academic au-
thors and the manufacturer and academic lead authorship.
When present, these features should alert readers to the
possibility that marketing is at work, and mandate careful
scrutiny of the article. But what of the details of framing,
methodology and reporting? Can readers be provided with
a simple checklist to spot bias at this level?
The answer, unfortunately, is no. As Barbour et al. cor-
rectly conclude, “individual trials have a unique combin-
ation of features reported in the journal publications.
The pattern of features makes marketing-influenced
studies difficult to identify by the average reader.” Cer-
tain features, such as uninformative comparisons, nonin-
feriority designs, surrogate or composite endpoints and
speculative conclusions, should raise concerns, but none
points with certainty to commercial bias, and in many
cases they are reasonable or agreed with regulators. Posi-
tive spin in the conclusions affects noncommercial as
well as commercial research, and is in any case encour-
aged by journals [33, 34]. Expert reading of articles by
clinicians in the field and authorities in trials design can
identify many flaws, and readers should seek independ-
ent commentaries and online forums for further insight.
However, perhaps the greatest difficulty with commercial
bias is that it can prove undetectable even by experts on
the basis of the information reported in the article, and
may only become fully apparent on rare occasions when
the manufacturer’s study reports and database trial data
are independently scrutinized [35]. Ultimately therefore,
the question of how to spot marketing tricks has a
troubling answer. In many cases, they cannot be spotted,
and certainly not by the everyday prescribers who are
this literature’s primary targets.
Solutions
Barbour et al. rightly argue that only independent research
can fully remedy these problems, but in its absence many
actions are possible. The concept of research integrity
should be recalibrated such that commercial secrecy, spin
and bias are viewed with the same gravity as individual fal-
sification and fraud. There have recently been encouraging
steps towards data sharing [36–38], but far more must
be done to ensure academics have ready access to all
commercial trials databases, study reports and protocols,
including data from past trials for licensed products, and
without undue red tape.
Among the various other possible interventions, I briefly
consider two. Firstly, two important resources, the
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CONSORT trial reporting standards and the Cochrane
Risk of Bias Tool [39, 40], require further development.
Good CONSORT compliance does not necessarily point
to high trial quality [41], and both CONSORT and the
commonly used trial assessment and bias tools have been
criticized for lack of scope and detail [42–44]. Commercial
biases may escape detection not only because they are
subtle or hidden in the published article, but because they
are poorly captured by the available bias categories. This
is particularly the case with what might be termed “design
bias” or “hard-wired bias” involving details such as the
choice of comparator, drug doses, dose escalation sched-
ules, efficacy criteria and adverse event coding [21, 44, 45].
The Cochrane Handbook for Systematic Reviews addresses
this difficulty in a number of ways and the Risk of Bias
Tool includes an “other biases” category [44], but the issue
remains poorly articulated. In some cases, CONSORT
compliance and favourable bias scores may have the unin-
tended effect of conferring credibility on research that
does not deserve it, and it is notable that advocates for the
commercial writing trade draw attention to the CON-
SORT compliance of the articles they develop as evidence
of their validity [46, 47]. These considerations challenge
the trials community to improve the guidance for report-
ing trials and assessing their quality, particularly in the set-
ting of industry research. The sheer diversity of potential
biases in commercial trials and their close relationship
with the clinical particularities of the trial setting may
make this a thorny task.
Secondly, what of Barbour’s primary concern, the journal
articles themselves? Many journals and their publishers
have substantial conflicts of interest in respect of industry,
whose trials fill their pages and whose reprint purchases
swell their revenues [48–50]. Journals dependent on indus-
try patronage have a financial incentive to publish com-
mercial research even when its importance is low, and to
allow trial reports to be framed and communicated in a
fashion which assists their marketing functions. Yet jour-
nals are the custodians of the academic medical canon and
have both responsibility and power to demand open data,
rigorous scientific and reporting standards and appropriate
attribution. Not all journals are fulfilling these responsibil-
ities with adequate scientific zeal, and because this problem
is enduring, systematic and potentially dangerous to pa-
tients, it should be considered as important a challenge to
the integrity of academic medical literature as research
misconduct.
There have been calls for journals to cease publishing
industry trials [51, 52], but a more realistic goal is to
raise journal standards. The International Committee of
Medical Journal Editors (ICMJE) guidelines recommend
a number of steps which improve the transparency of
commercial literature, but they remain permissive of
pharmaceutical marketing [53]. No article should be
deemed acceptable for journal publication without the
accompanying publication of the trial protocol, com-
pleted to SPIRIT standards [54], an unsparing account of
the work’s scientific and clinical limitations, and prompt
access to patient-level data and clinical study reports.
Furthermore, since the flaws and biases in this literature are
often difficult for readers to identify, a stronger onus should
be placed on the trials’ own stakeholders to report any
features which might favour the product, as a matter of
research integrity. Altman and Moher have called for jour-
nals to require lead authors to make a signed declaration of
the work’s honesty, accuracy and transparency [55], and
building upon this approach, journals should require
authors and product manufacturers to supply detailed
Table 2 Developing an author-completed checklist for journal
articles reporting industry trials
Items for inclusion in checklist
A. Commercial aspects of the study
• Identification of all stakeholders, including manufacturer, agencies,
academic institutions, authors, contributors
• Who instigated the research?
• How was it financed? Total, majority or minority finance from
manufacturer?
• Identify main product of commercial interest
• Frank statement of the commercial relevance of the research (e.g.
securing approval, demonstrating advantage over competitor,
providing practical experience of product)
• Details of intellectual property/data ownership and summary of data
sharing plan
• Details of all recent payments by manufacturer to participating
institutions, agencies, authors and contributors
• Confirmation that all author/contributor interests are registered on a
public website
• Public URL for all commercial publications plans in which the article
is listed
• Consent for journal to publish number of reprint/eprint sales for article
B. Study design, analysis, interpretation and reporting
• Clear characterization of company and agency role
• Confirmation of compliance with reporting guidelines (CONSORT
guidelines should be upgraded)
• Provide point-by-point response to checklist of design features,
identifying those potentially favouring the product or limiting the
applicability of the study. Examples: Patient selection; Choice of control
treatment; Doses and regimens; Run-in period; Assessment criteria;
Safety definitions; Cut-off points for data inclusion; Deviations from
protocol; Early stopping; etc.
Responsibilities for journals
• Ensure full checklists are provided with submission, signed off by
the corresponding author and company representative
• Ensure peer reviewers are provided with completed checklist
• Use checklist to:
° Ensure potential methodological biases and design features likely
to favour the product or limit the study’s applicability are fully
described and prominently tabulated in the published article
° Check commercial roles and goals are prominently described in
the article
° Check attribution, labelling and disclosures reflect true role of the
company, e.g. name manufacturer in title of article; place article in
designated “industry trials” section of journal
• Publish completed checklists online for published articles
• Publish reprint purchase numbers for all articles
• Consider corrections, retraction, referral to research integrity office and
legal action if checklist proves to have been inaccurately completed
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information on the commercial provenance and design fea-
tures of the work, a task that could be accomplished using
a checklist (Table 2).
The uncomfortable truth, however, is that journals and
publishing corporations inured to industry patronage are
unlikely to seek reform of a culture in which they pros-
per. One final possibility might therefore be the develop-
ment of a new editorial standard, supplementary to that
of the ICMJE and more exacting, for journals committed
to rigorous science and reporting. If readers came to
recognize the standard and its logo as a mark of scien-
tific stringency, this might stimulate wider uptake by
journals and raise the quality of clinical trial reporting.
Conclusions
Pharmaceutical research produces innovative, life-saving
medicines which should be celebrated, but it is also under-
mined by marketing, leading to trials of marginal scientific
interest, widespread product seeding and the systematic
penetration of marketing bias, much of it subtle or hidden,
into the broader clinical trials literature. Manufacturers
are de facto corporate authors of much of this research,
but the published literature is spun to give the impression
of academic-led projects. The “marketing” or “seeding”
trial represents only one, variably defined point within a
spectrum of undesirable commercial influence. Barbour et
al. rightly argue that the most effective solution to these
challenges is independent research, but in addition, ready
data access, upgraded CONSORT guidance, more detailed
bias assessment tools and more exacting editorial require-
ments have a role to play. Journals have a critical responsi-
bility to enforce exacting scientific and communicative
standards, but many titles which prosper from industry
patronage are failing in this duty, to the detriment of
medicine.
I congratulate Barbour et al. on their important study.
They describe their research as “more suited to start a
debate than to settle it”, and my analysis and the remedies
I have considered follow in the same spirit. I encourage
others to join the conversation.
Additional file
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